Acquisition of Laprolan B.V. from Fornix BioSciences N.V. (Details)	12 Months Ended		3 Months Ended	9 Months Ended				12 Months Ended
	Sep. 30, 2011 Decrease in goodwill USD ($)	Sep. 30, 2011 Decrease in deferred tax liabilities USD ($)	Jun. 30, 2011 Laprolan B.V. USD ($)	Jun. 30, 2011 Laprolan B.V. USD ($)	Jun. 30, 2012 Laprolan B.V. USD ($)	Jan. 01, 2011 Laprolan B.V. USD ($)	Jan. 01, 2011 Laprolan B.V. EUR (€)	Sep. 30, 2011 Laprolan B.V. Decrease in goodwill USD ($)	Sep. 30, 2011 Laprolan B.V. Decrease in deferred tax liabilities USD ($)
Acquisition of Laprolan B.V. from Fornix BioSciences N.V.
Purchase price paid to Fornix						$ 15,057,775	€ 10,474,974
Purchase price paid in cash						60,217
Interest paid						119,433
Goodwill acquired					5,602,000
Finite-lived intangibles acquired					5,612,000
Reduction in goodwill and deferred tax liabilities (in dollars)	(669,350)	669,350						(669,000)	669,000
Fair values of the assets and liabilities acquired
Current assets					3,212,000
Property and equipment					1,831,000
Intangible assets					10,545,000
Total assets acquired					15,588,000
Current liabilities					824,000
Long term liabilities					877,000
Total liabilities assumed					1,701,000
Pro forma unaudited results of operations
Net sales			14,281,000	40,794,000
Net income (loss)			29,000	(596,000)
Per share data:
Net loss per share - basic (in dollars per share)			$ 0.00	$ (0.05)
Net loss per share - diluted (in dollars per share)			$ 0.00	$ (0.05)
Decrease in net loss for one-time merger and acquisition costs			304,000	695,000
Decrease in net loss related to a short term accounting and IT support contract			$ 19,000	$ 45,000